Prothena Corp PRTA

$8.40 +0.05 (0.60%)

Valuation

Market cap
424,151,000
Revenue TTM
$9,680,000
Net income TTM
$-244,090,000
P/E (trailing)
0.00
P/E (forward)
144.91
Profit margin
-2,521.59%
Debt to equity
0.00

Trading

Volume
566,900
Avg volume
517,206
Day's range
$8.17 – $8.49
Shares out
51,350,000
Stochastic %K
57%
Beta
-0.20
Analysts
Moderate Buy
Price target
$19.33

Price

Company profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an inve...

Show more

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Industry
Biotechnology
Sector
Healthcare
Phone
353 1 236 2500
Website
https://www.prothena.com
Address
77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland

Latest news

Stocktwits

LALC_Capital Nov 19, 7:25 PM
$PRTA more buying at our oct 19 pick. 10% holder William Scully bought 50,000 more shares on the open market on 17 Nov at an average of about 8.09, about 405K in all. Not a pre-set plan buy. It follows his 140,000 shares on 9 Nov at about 8.53, and his 13G/A filed last week put him at about 12.5% of the company. Form 4: https://www.sec.gov/Archives/edgar/data/1559053/000104546326000027/0001045463-26-000027-index.htm
0 replies
magic_clown Nov 19, 7:24 PM
$PRTA 👀 👀 👀
0 replies
LALC_Capital Nov 11, 6:06 PM
$PRTA update on our Oct 19 pick: 10% holder William Scully bought another 140,000 shares on the open market on 9 Nov at about 8.53, about 1.19M in all. He holds 977,000 directly after gifting about 916K on 6 Nov. Our pick price was 8.35. Form 4: https://www.sec.gov/Archives/edgar/data/1045463/000104546326000024/xslF345X06/primary_doc.xml
0 replies
SayZero Nov 11, 2:06 PM
$PRTA I find any shorts on this company are truly disgusting human beings.
0 replies
LALC_Capital Nov 5, 9:21 PM
$PRTA update on our Oct 19 pick Prothena. Q3 R&D fell to 8.4M from 28.9M a year ago and the net loss narrowed to 16.5M from 36.5M, though Q3 revenue was only 0.6M vs 2.4M. Cash and equivalents were 271.4M at Sep 30, down from 307.5M in December, and the company has bought back 2.75M shares this year for 26.6M (501K in Q3). No debt. It guides to about 259M of cash at year end, not counting any further buybacks. The 100M buyback program expires Dec 31. Does it get renewed? Filing: https://www.sec.gov/Archives/edgar/data/1559053/000155905326000030/exhibit991q32026earningsre.htm
0 replies
JmaxUP Nov 5, 7:51 PM
$GANX $PRTA $NVO $PFE considering the vix is 24 now. I bought more of these stocks. Will be buy more when the vix goes higher. If vix go lower instead, a good chance these stock price go up.
0 replies
JmaxUP Nov 4, 12:30 AM
$PRTA below are the drugs they are making. I like all of it and hope all of it work. My family need these and willing to pay to give a try. • Prasinezumab (for Parkinson's): Acts like a shield to stop a bad protein (α-synuclein) from spreading and damaging brain cells. (Partnered with Roche) • Coramitug (for Heart Disease): Targets misfolded proteins that build up in the heart and cause a rare, dangerous stiffness. (Partnered with Novo Nordisk) • Moponetug (for Alzheimer's): Aims to stop a protein called "Tau" from creating toxic tangles inside brain cells. (Partnered with Bristol Myers Squibb) • PRX012 (for Alzheimer's): Designed to clear out the sticky plaques that block brain signals, though early tests showed it can cause some brain swelling side effects.
0 replies
OnlyFibs Nov 1, 4:21 AM
$PRTA 🚨 TESTING INSTITUTIONAL BUY ZONE | $9 CALL SWEEP 🚨 $PRTA is compressing inside its $8.20 – $8.80 Institutional Buy Zone on the 8H chart! Wedge apex compression holding strong as unexpired call sweep hits demand. 📊 CHART ZONES & FLOW ($PRTA, 8H): • Smart Money Sell: $10.20 – $11.00 • Institutional Sell: $9.40 – $10.00 • Institutional Buy: $8.20 – $8.80 (CURRENT LOAD) • Smart Money Buy: $7.80 – $8.15 • Active Flow: $50.5K sweep on 12/18 $9 Calls @ Ask ($0.60) 🎯 KEY LEVELS: 🐂 Bull Trigger: Defend $8.00 & reclaim $9.00 to target $9.80+. 🐻 Bear Trigger: 8H close below $7.75. BIAS: Tactical Wedge Reversal / Long off Demand 📊📈 #hovdid
0 replies